AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.26

Change

-0.04 (-1.74)%

Market Cap

USD 0.61B

Volume

1.72M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 84.94B
ARGX argenx NV ADR

N/A

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.66B
BGNE BeiGene Ltd

N/A

USD 20.24B
UTHR United Therapeutics Corporatio..

N/A

USD 16.18B
MRNA Moderna Inc

N/A

USD 16.10B
RPRX Royalty Pharma Plc

N/A

USD 15.05B
SMMT Summit Therapeutics PLC

N/A

USD 13.67B
INCY Incyte Corporation

N/A

USD 13.52B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
ITB iShares U.S. Home Constru.. 4.38 % 0.42 %

N/A

N/A
RFG Invesco S&P MidCap 400® .. 1.79 % 0.35 %

N/A

N/A
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
AFMC First Trust Active Factor.. 1.22 % 0.00 %

N/A

USD 0.03B
WDSC:LSE SPDR MSCI World Small Cap.. 0.20 % 0.00 %

N/A

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.20 % 0.00 %

N/A

N/A
ZPRS:F SSgA SPDR ETFs Europe II .. 0.20 % 0.00 %

N/A

USD 0.83B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.20 % 0.00 %

N/A

USD 0.83B
IUSN:XETRA iShares MSCI World Small .. 0.20 % 0.00 %

N/A

USD 3.82B
EZM WisdomTree U.S. MidCap Ea.. 0.00 % 0.38 %

N/A

N/A
ONEO SPDR® Russell 1000 Momen.. 0.00 % 0.20 %

N/A

N/A
VAMO Cambria Value and Momentu.. 0.00 % 0.64 %

N/A

N/A
XHB SPDR® S&P Homebuilders E.. 0.00 % 0.35 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
IUSN:F iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.91% 25% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.91% 25% F 11% F
Trailing 12 Months  
Capital Gain -64.91% 25% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.91% 25% F 11% F
Trailing 5 Years  
Capital Gain -83.39% 40% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.39% 40% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain 0.14% 48% F 39% F
Dividend Return 0.14% 47% F 34% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.79% 45% F 26% F
Risk Adjusted Return 0.17% 47% F 34% F
Market Capitalization 0.61B 75% C 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector